Conference Coverage

Inotuzumab continues to wow against relapsed/refractory ALL


 

At THE EHA CONGRESS

References

The study was funded by Pfizer. Dr. Kantarjian disclosed research support from the company. Dr. Izraeli reported having no relevant disclosures.

Pages

Next Article: